AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30363041 — intervention group
Group type: EXPERIMENTAL
Intervention: RT performed 6 times per week (RT6)
Number of subjects: 27
Study 27939108 — intervention group
Group type: EXPERIMENTAL
Intervention: Microstream side stream capnography device (quantitative)
Number of subjects: 59
Study 27939108 — intervention group
Group type: COMPARATOR
Intervention: Disposable PediCap EtCO2 detector (qualitative)
Number of subjects: 59
Study 27939108 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (quantitative and qualitative)
Number of subjects: 59
Study 24947459 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced 6% HES130/0.42
Number of subjects: 50
Study 24947459 — intervention group
Group type: COMPARATOR
Intervention: Ringer-acetate solution
Number of subjects: 50
Study 23803275 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth DSS with integrated CIS resources
Number of subjects: 156
Study 21859411 — intervention group
Group type: EXPERIMENTAL
Intervention: Poetry writing intervention
Number of subjects: 0
Study 18940024 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition (building-site noise at 75 dB with difficult knowledge questions)
Number of subjects: 64
Study 18940024 — intervention group
Group type: COMPARATOR
Intervention: Non-stress condition
Number of subjects: 64
Study 17176348 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection practices assessment
Number of subjects: 1150
Study 14760332 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of carvedilol twice daily
Number of subjects: 174
Study 14760332 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of carvedilol twice daily
Number of subjects: 174
Study 14760332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 11156100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue valves
Number of subjects: 0
Study 11156100 — intervention group
Group type: COMPARATOR
Intervention: Mechanical valves
Number of subjects: 0
Study 9494595 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 300 mg i.v. for 3 days, followed by oral clodronate 3200 mg for four weeks
Number of subjects: 55
Study 9494595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 9494595 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate
Number of subjects: 55
Study 8472160 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg twice daily
Number of subjects: 44
Study 8472160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 2411103 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nasal decongestants
Number of subjects: 61
Study 2411103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 31137724 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep ocean mineral water (DOM)
Number of subjects: 9
Study 31137724 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 9
Study 30867278 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice of analgesic protocol (low: 50 μg intrathecal morphine, medium: 150 μg intrathecal morphine, high: 300 μg intrathecal morphine with 600 mg oral gabapentin)
Number of subjects: 160
Study 30867278 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose group (300 μg intrathecal morphine with 600 mg oral gabapentin)
Number of subjects: 160
Study 30867278 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose group (50 μg intrathecal morphine)
Number of subjects: 160
Study 28233752 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-tract technique
Number of subjects: 61
Study 28233752 — intervention group
Group type: COMPARATOR
Intervention: Coaxial technique
Number of subjects: 61
Study 25524791 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic stimulant treatment
Number of subjects: 0
Study 25524791 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of stimulants and behavioral treatment
Number of subjects: 0
Study 25524791 — intervention group
Group type: COMPARATOR
Intervention: Behavioral management
Number of subjects: 0
Study 25524791 — intervention group
Group type: COMPARATOR
Intervention: Routine community care
Number of subjects: 0
Study 25524791 — intervention group
Group type: COMPARATOR
Intervention: Medication alone
Number of subjects: 0
Study 25524791 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent- and teacher-reported ADHD symptoms
Number of subjects: 0
Study 23953963 — intervention group
Group type: EXPERIMENTAL
Intervention: 61% high porosity asymmetric titanium porous surface (StikTite, Smith and Nephew, TN, USA)
Number of subjects: 62
Study 23953963 — intervention group
Group type: COMPARATOR
Intervention: 45% low porosity sintered bead porous surface (Roughcoat, Smith and Nephew, TN, USA)
Number of subjects: 62
Study 21519338 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine treatment at standard doses
Number of subjects: 100
Study 21519338 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine treatment
Number of subjects: 100
Study 21519338 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A43 genotype analysis
Number of subjects: 100
Study 18827109 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic treatment
Number of subjects: 11
Study 17176376 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured activities intervention group (300 children)
Number of subjects: 400
Study 17176376 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (50 children from Gaza and 50 children from the West Bank)
Number of subjects: 400
Study 14513417 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-drug salvage regimen after 12 weeks of structured treatment interruption (STI)
Number of subjects: 46
Study 14513417 — intervention group
Group type: COMPARATOR
Intervention: 5-drug salvage regimen immediately (noninterruption [NI] group])
Number of subjects: 46
Study 14513417 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-drug salvage regimen
Number of subjects: 46
Study 10846380 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam lollipop (5 mg)
Number of subjects: 175
Study 10846380 — intervention group
Group type: COMPARATOR
Intervention: Atropine lollipop (0.25 mg)
Number of subjects: 175
Study 10846380 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and atropine lollipop (5 mg midazolam and 0.25 mg atropine)
Number of subjects: 175
Study 9233738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 61
Study 9233738 — intervention group
Group type: COMPARATOR
Intervention: Atracurium
Number of subjects: 61
Study 8481222 — intervention group
Group type: EXPERIMENTAL
Intervention: Kava-special extract WS 1490 (3 x 100 mg/d over 8 days)
Number of subjects: 40
Study 8481222 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study 3436155 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomod (75 mg sustained-release indomethacin)
Number of subjects: 18
Study 3436155 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocid R (25 mg normal, 50 mg sustained-release indomethacin)
Number of subjects: 18
Study 3436155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3436155 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomod
Number of subjects: 18
Study 29962920 — intervention group
Group type: EXPERIMENTAL
Intervention: Moringa oleifera leaf powder (MLP) fortified foods (MCL-35g and MS-5g)
Number of subjects: 103
Study 29962920 — intervention group
Group type: COMPARATOR
Intervention: Control food (CF-35g, a cereal legume blend)
Number of subjects: 103
Study 28232097 — intervention group
Group type: EXPERIMENTAL
Intervention: TF ACD group
Number of subjects: 0
Study 28232097 — intervention group
Group type: EXPERIMENTAL
Intervention: MIX ACD group
Number of subjects: 0
Study 28232097 — intervention group
Group type: EXPERIMENTAL
Intervention: PF ACD group
Number of subjects: 0
Study 28232097 — intervention group
Group type: COMPARATOR
Intervention: HC group
Number of subjects: 0
Study 28232097 — intervention group
Group type: EXPERIMENTAL
Intervention: PF group
Number of subjects: 0
Study 28232097 — intervention group
Group type: EXPERIMENTAL
Intervention: TF and MIX groups
Number of subjects: 0
Study 25605515 — intervention group
Group type: COMPARATOR
Intervention: Macroscopic serosal changes identified intraoperatively in 432 patients (66%)
Number of subjects: 655
Study 25605515 — intervention group
Group type: COMPARATOR
Intervention: Macroscopic serosal changes
Number of subjects: 655
Study 23966331 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol-binding protein 4
Number of subjects: 500
Study 23966331 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D-binding protein
Number of subjects: 500
Study 23966331 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein C-III
Number of subjects: 500
Study 23966331 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruloplasmin
Number of subjects: 500
Study 23966331 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenoprotein P isoform 1
Number of subjects: 500
Study 20195164 — intervention group
Group type: EXPERIMENTAL
Intervention: CGES at tachygastrial frequency (12 cycles/min)
Number of subjects: 20
Study 20195164 — intervention group
Group type: COMPARATOR
Intervention: CGES at physiologic frequency (3 cycles/min)
Number of subjects: 20
Study 18157013 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer (CIK) cells therapy
Number of subjects: 85
Study 18157013 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy
Number of subjects: 85
Study 16979496 — intervention group
Group type: EXPERIMENTAL
Intervention: Single low-level laser therapy (LLLT); Mini Laser 2075, Helbo Photodynamic Systems GmbH & Co KG, Linz, Austria; wavelength 670 nm, power output 75 mW; duration 30 seconds per banded tooth
Number of subjects: 76
Study 16979496 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser therapy without active laser irradiation
Number of subjects: 76
Study 14575385 — intervention group
Group type: COMPARATOR
Intervention: 99mTc‐GSA dynamic SPECT study pre-operative
Number of subjects: 54
Study 14575385 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐GSA dynamic SPECT study post-operative
Number of subjects: 54
Study 10930199 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethylstarch (HES) 10% 500 ml
Number of subjects: 40
Study 10930199 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LR) 1 L
Number of subjects: 40
Study 10930199 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 8674483 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure (0.4 ppm for 2 hr)
Number of subjects: 10
Study 2245382 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy (3150 cGy in 18 fractions, 2 to 3 weeks before surgery)
Number of subjects: 309
Study 2245382 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy
Number of subjects: 309
Study 2245382 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative radiation)
Number of subjects: 309
Study 654857 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide, 1 mg/kg b.w.
Number of subjects: 16
Study 654857 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol, 0.5 g/kg b.w.
Number of subjects: 16
Study 31531854 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl intravenous patient-controlled analgesia
Number of subjects: 22144
Study 31531854 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic predictive model
Number of subjects: 22144
Study 30003833 — intervention group
Group type: EXPERIMENTAL
Intervention: Reslizumab
Number of subjects: 0
Study 30003833 — intervention group
Group type: COMPARATOR
Intervention: Placebo effect model
Number of subjects: 0
Study 30003833 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 0
Study 28662208 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 91
Study 28662208 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Cognitive Therapy (MBCT)
Number of subjects: 91
Study 28662208 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 91
Study 25027945 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (1MAC, 5-6%)
Number of subjects: 31
Study 25027945 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.5-2%)
Number of subjects: 31
Study 23253266 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT)
Number of subjects: 26
Study 23253266 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 26
Study 22068809 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 66
Study 22068809 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin
Number of subjects: 66
Study 22068809 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of both
Number of subjects: 66
Study 18076072 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital malformations
Number of subjects: 191
Study 18076072 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal history of spontaneous abortions
Number of subjects: 191
Study 17044456 — intervention group
Group type: EXPERIMENTAL
Intervention: Sureflux 150E (cellulose triacetate)
Number of subjects: 17
Study 17044456 — intervention group
Group type: COMPARATOR
Intervention: AV-400 (standard synthetic membrane)
Number of subjects: 17
Study 15189628 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-enhancement values salient
Number of subjects: 0
Study 15189628 — intervention group
Group type: COMPARATOR
Intervention: Self-transcendence values salient
Number of subjects: 0
Study 11068117 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-traumatic lidocaine infusion (30 min prior to heat trauma)
Number of subjects: 6
Study 11068117 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-traumatic lidocaine infusion (immediately after heat trauma)
Number of subjects: 6
Study 11068117 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lidocaine)
Number of subjects: 6
Study 11068117 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary hyperalgesia (both pre- and post-traumatic lidocaine)
Number of subjects: 6
Study 9414074 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-resistance strength training
Number of subjects: 24
Study 8338043 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin A supplementation
Number of subjects: 0
Study 8338043 — intervention group
Group type: COMPARATOR
Intervention: Control group (unsupplemented women)
Number of subjects: 0
Study 8338043 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC
Number of subjects: 0
Study 2883920 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (200 mg single dose)
Number of subjects: 24
Study 2883920 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg single dose)
Number of subjects: 24
Study 2883920 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (200 mg daily for three weeks)
Number of subjects: 24
Study 2883920 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg daily for three weeks)
Number of subjects: 24
Study 30465369 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion (300μg in 100ml over 3 minutes)
Number of subjects: 90
Study 30465369 — intervention group
Group type: COMPARATOR
Intervention: Haemocoel preload (500 ml before spinal anaesthesia)
Number of subjects: 90
Study 26762672 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-fampridine (10 mg, twice daily)
Number of subjects: 55
Study 26762672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 24907876 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral spinal anesthesia with 2.5 cm(3) of hyperbaric bupivacaine
Number of subjects: 0
Study 24907876 — intervention group
Group type: COMPARATOR
Intervention: Bilateral spinal anesthesia with 1.5 cm(3) of hyperbaric bupivacaine
Number of subjects: 0
Study 22426704 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized foot orthotics along with spinal exercise therapy and analgesics (Orthotics group)
Number of subjects: 67
Study 22426704 — intervention group
Group type: COMPARATOR
Intervention: Spinal exercise therapy and analgesics (Control group)
Number of subjects: 67
Study 20637147 — intervention group
Group type: EXPERIMENTAL
Intervention: nSIMV
Number of subjects: 50
Study 20637147 — intervention group
Group type: COMPARATOR
Intervention: nCPAP
Number of subjects: 50
Study 18356664 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 peritumoral (PT) injections
Number of subjects: 192
Study 18356664 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 subdermal (SD) injection of Tc‐99m rhenium sulfide colloid
Number of subjects: 192
Study 18356664 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 PT and 1 SD combined injections
Number of subjects: 192
Study 18356664 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 intradermal periareolar (ID‐PA) injections
Number of subjects: 192
Study 18356664 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ID‐PA and 1 PT combined injections
Number of subjects: 192
Study 18356664 — intervention group
Group type: COMPARATOR
Intervention: PT and SD injection groups
Number of subjects: 192
Study 15751813 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 0
Study 12094339 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/paclitaxel
Number of subjects: 480
Study 12094339 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine/cisplatin
Number of subjects: 480
Study 12094339 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine/paclitaxel
Number of subjects: 480
Study 10482007 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol-17 propionate lotion under hydrocolloid dressing (Duoderm ET) once weekly
Number of subjects: 0
Study 10482007 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol-17 propionate ointment without an HCD twice daily
Number of subjects: 0
Study 10482007 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 0
Study 8690806 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of bovine myelin
Number of subjects: 34
Study 8690806 — intervention group
Group type: COMPARATOR
Intervention: Nontreated patients
Number of subjects: 34
Study 1480737 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (daily doses ranged from 250 to 2100 mg)
Number of subjects: 91
Study 1480737 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 91
Study 1480737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 1480737 — intervention group
Group type: COMPARATOR
Intervention: Lithium and Placebo
Number of subjects: 91
Study 6238338 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg paroxetine
Number of subjects: 5
Study 6238338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31295048 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who received ≥1 dose of HPV vaccine
Number of subjects: 3261
Study 31295048 — intervention group
Group type: COMPARATOR
Intervention: Women who did not receive HPV vaccine (unvaccinated)
Number of subjects: 3261
Study 31295048 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated women vs. unvaccinated women
Number of subjects: 3261
Study 31295048 — intervention group
Group type: COMPARATOR
Intervention: Vaccinated mothers vs. unvaccinated mothers
Number of subjects: 3261
Study 30275094 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 154
Study 24685886 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan/Docetaxel (Arm A)
Number of subjects: 87
Study 24685886 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan/Docetaxel/Cetuximab (Arm B)
Number of subjects: 87
Study 23857741 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of hs-CRP
Number of subjects: 2910
Study 23857741 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP
Number of subjects: 2910
Study 23427389 — intervention group
Group type: EXPERIMENTAL
Intervention: PKP plus Zishengukang (ZSGK) - 6 g orally three times a day for 90 days after PKP
Number of subjects: 70
Study 23427389 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous kyphoplasty (PKP) alone
Number of subjects: 70
Study 20634962 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstacle one (illusion made it appear larger)
Number of subjects: 50
Study 20634962 — intervention group
Group type: EXPERIMENTAL
Intervention: After 50 crossings
Number of subjects: 50
Study 20634962 — intervention group
Group type: EXPERIMENTAL
Intervention: First five obstacle crossings (1-5)
Number of subjects: 50
Study 20634962 — intervention group
Group type: EXPERIMENTAL
Intervention: Last five obstacle crossings (46-50)
Number of subjects: 50
Study 18263771 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy
Number of subjects: 0
Study 18263771 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticancer agents
Number of subjects: 0
Study 16510370 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin XL 80 mg
Number of subjects: 94
Study 16510370 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg
Number of subjects: 94
Study 15112850 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA) with isobaric 0.5% bupivacaine 3-3.5 ml intrathecally and 15 ml of bupivacaine with 1/200,000 epinephrine for wound infiltration
Number of subjects: 0
Study 15112850 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 0
Study 10703470 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 G needle
Number of subjects: 100
Study 10703470 — intervention group
Group type: COMPARATOR
Intervention: 12 G needle
Number of subjects: 100
Study 8768637 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation with midazolam prior to surgery
Number of subjects: 30
Study 8768637 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation with midazolam until the end of surgery
Number of subjects: 30
Study 1897688 — intervention group
Group type: EXPERIMENTAL
Intervention: L-648,051 (800 micrograms) inhaled during the immediate phase (15 min after antigen challenge)
Number of subjects: 12
Study 1897688 — intervention group
Group type: EXPERIMENTAL
Intervention: L-648,051 (800 micrograms) inhaled before antigen challenge (5 min before)
Number of subjects: 12